2024
Rare Breast Tumors
Harigopal M, Podany P, Andrejeva L, Singh K. Rare Breast Tumors. 2024, 343-374. DOI: 10.1007/978-3-031-65711-5_13.Peer-Reviewed Original ResearchSubtypes of breast cancerBreast cancerRare subtypeWorld Health OrganizationRare subtype of breast cancerHistological subtype of breast cancerWorld Health Organization Classification of TumorsCore needle biopsy specimensWorld Health Organization classificationTall cell carcinomaNeedle biopsy specimensRare histologic typeClassification of tumorsRare cancer typesRare tumorHistological subtypesHistological typeCell carcinomaUnusual subtypeBiopsy specimensPrognostic implicationsGenetic alterationsHistological featuresHistologic cluesAncillary testsRadiologic-Pathologic Correlation of Cardiac Tumors: Updated 2021 WHO Tumor Classification.
Lorca M, Chen I, Jew G, Furlani A, Puri S, Haramati L, Chaturvedi A, Velez M, Chaturvedi A. Radiologic-Pathologic Correlation of Cardiac Tumors: Updated 2021 WHO Tumor Classification. RadioGraphics 2024, 44: e230126. PMID: 38722782, DOI: 10.1148/rg.230126.Peer-Reviewed Educational MaterialsConceptsCardiac tumorsClassification of tumorsCardiac massWorld Health OrganizationCharacterization of cardiac massesWorld Health Organization Classification of TumorsWorld Health Organization tumor classificationWorld Health Organization classificationMalignant cardiac massesPrimary cardiac tumorsPrimary cardiac neoplasmsCardiac metastasisPapillary fibroelastomaThoracoabdominal CTCardiac CTCardiac neoplasmsIntracardiac massesNoncardiac indicationsSurgical managementRadiological investigationsTumor biologyTumor typesCardiac MRIAnatomical variantsTreatment planningGlioblastom – aktuelle Therapiekonzepte
Rieger D, Renovanz M, Kurz S, Bombach P, Paulsen F, Roder C, Tatagiba M, Niyazi M, Tabatabai G. Glioblastom – aktuelle Therapiekonzepte. Die Onkologie 2024, 30: 145-156. DOI: 10.1007/s00761-024-01473-7.Peer-Reviewed Original ResearchClinical trialsWorld Health Organization classificationCombination of radiotherapyFirst-line therapyDiagnosis of glioblastomaPatterns of disease progressionTherapeutic clinical trialsTumor Treating FieldsCurrent treatment conceptsCentral nervous systemNeuro-oncology careTemozolomide chemotherapyFirst-linePostoperative therapyPrimary neoplasmsOrganization classificationUnfavorable prognosisTumor progressionClinical statusDisease progressionTreatment conceptTreatment recommendationsBiomarker-basedNervous systemGlioblastoma
2023
Recent Advances in Genitourinary Tumors: Updates From the 5th Edition of the World Health Organization Blue Book Series.
Riddle N, Parkash V, Guo C, Shen S, Perincheri S, Ramirez A, Auerbach A, Belchis D, Humphrey P. Recent Advances in Genitourinary Tumors: Updates From the 5th Edition of the World Health Organization Blue Book Series. Archives Of Pathology & Laboratory Medicine 2023, 148: 952-964. PMID: 38031818, DOI: 10.5858/arpa.2022-0509-ra.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMale genital tumorsWorld Health Organization classificationGenital tumorsOrganization classificationClinical practiceDate clinical practiceRoutine clinical practiceWorld Health OrganizationUrinary tumorsGenitourinary tumorsSimilar tumorsDiagnostic criteriaTumor seriesTumorsGenetic syndromesOrgan systemsHealth OrganizationComprehensive updateUrinaryNew entitySyndromeGenomic terminologyComparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis
Iastrebner M, Zeidan A, Arbelbide J, Velloso E, Pereira T, Boada M, Crisp R, Pereyra P, Reyes J, Zappa M, perez-Jacobo F, Dela Peña Celaya J, Moreno E, Abello V, Solano M, Cuervo D, Espinosa D, Casas C, Montoya L, Enrico A, Prates V, Chavez E, Ontiveros-Austria J, Kornblihtt L, Leon A, Toledo V, Negri L, Serrano J, Sánchez A, Rodriguez-Zuñiga A, Stevenazzi M, Goldschmidt V, Grille S. Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis. Blood 2023, 142: 5179. DOI: 10.1182/blood-2023-185122.Peer-Reviewed Original ResearchProgression-free survivalTime of diagnosisAcute myeloid leukemiaMDS-MLDOverall survivalMDS patientsMDS-RSInternational Prognostic Scoring SystemLow-risk MDS patientsWorld Health Organization classificationLR-MDS patientsMedian blast countRisk MDS patientsCohort of patientsKaplan-Meier methodPrognostic scoring systemClassification of patientsNon-Hispanic whitesMDS-EB2PFS probabilityWHO 2016Baseline characteristicsBlast countMedian ageMeier methodClassification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational consensus classificationResponse assessmentWorld Health Organization classificationPatient-centered careRisk assessment toolClinical outcomesRisk stratificationOrganization classificationCentered careTherapeutic benefitTherapeutic outcomesConsensus classificationResponse criteriaInternational ConsortiumNeoplasmsLife assessmentAssessment toolOutcomesReportAssessmentPrognosticationCareClinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience
González I, Torbenson M, Sharifai N, Byrnes K, Chatterjee D, Kakar S, Yeh M, Wu T, Zhang X, Jain D. Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Human Pathology 2023, 138: 24-33. PMID: 37245629, DOI: 10.1016/j.humpath.2023.05.010.Peer-Reviewed Original ResearchConceptsHepatocellular adenomaHepatocellular carcinomaMalignant transformationMulticenter experienceMean ageWorld Health Organization classificationConcomitant hepatocellular carcinomaAndrogen receptor expressionBenign liver neoplasmUnclassified hepatocellular adenomaUncertain malignant potentialInflammatory hepatocellular adenomaΒ-catenin-activated hepatocellular adenomaClinicopathologic characterizationEntire cohortHCA casesCommon subtypeMalignant potentialOrganization classificationReproductive ageAllred score systemResection casesReceptor expressionHepatocellular neoplasmsLiver neoplasmsMulticenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant Glioma
Fanucci K, Pilat M, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman F, Gonzalez J, Giglio P, Ivy S, Bindra R, Omuro A, LoRusso P. Multicenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant Glioma. Cancer Research Communications 2023, 3: 192-201. PMID: 36968138, PMCID: PMC10035510, DOI: 10.1158/2767-9764.crc-22-0436.Peer-Reviewed Original ResearchConceptsProgression-free survivalMedian progression-free survivalProlonged stable diseaseStable diseasePhase II trialGrade 4 tumorsII trialOlaparib monotherapyGrade 2Multicenter phase 2 trialSingle-arm phase II trialWorld Health Organization classificationMedian overall survivalNeuro-Oncology criteriaPhase 2 trialOverall response rateFuture patient stratificationMutant gliomasPARP inhibitor olaparibEvaluable patientsPrimary endpointOverall survivalProgressive diseaseSelect patientsClinical benefitUpdate of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone
Wang A, Maloney E, Al-Dasuqi K, Irshaid L, Ahmed A, Haims A, Porrino J. Update of pediatric bone tumors—other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone. Skeletal Radiology 2023, 52: 1443-1463. PMID: 36656343, DOI: 10.1007/s00256-023-04286-8.Peer-Reviewed Original ResearchConceptsUndifferentiated small round cell sarcomaSmall round cell sarcomasBone tumorsRound cell sarcomasPediatric populationCell sarcomaMesenchymal tumorsHematopoietic neoplasmsWorld Health Organization classificationGiant cell-rich tumorsPediatric bone tumorsOsteogenic tumorsOrganization classificationVascular tumorsNotochordal tumorsTumorsGenetic sequencing techniquesChondrogenic tumorsCertain lesionsSoft tissueBoneSarcomaNeoplasmsSeparate manuscriptDetailed updateRecent Advances in the Classification of Gynecological Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".
Parkash V, Aisagbonhi O, Riddle N, Siddon A, Panse G, Fadare O. Recent Advances in the Classification of Gynecological Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book". Archives Of Pathology & Laboratory Medicine 2023, 147: 1204-1216. PMID: 36596270, DOI: 10.5858/arpa.2022-0166-ra.Peer-Reviewed Original ResearchConceptsWorld Health Organization classificationOrganization classificationWorld Health OrganizationTract tumorsGynecological tumorsFemale genital tract tumorsHealth OrganizationGenital tract tumorsHuman papillomavirus associationFemale genital tumorsLower genital tractFallopian tube tumorsRoutine clinical practiceGenetic tumor syndromesSite of originGenital tumorsGenital tractDiagnostic criteriaGlandular lesionsClinical practiceTumor syndromeTumorsComprehensive updateSyndromeLesions
2022
Impact of Pre-Existing Ischemic Heart Disease on Severe Maternal Morbidity and Mortality During Delivery Hospitalizations
Denoble A, Goldstein S, Wein L, Grotegut C, Federspiel J. Impact of Pre-Existing Ischemic Heart Disease on Severe Maternal Morbidity and Mortality During Delivery Hospitalizations. JACC Advances 2022, 1: 100157. PMID: 36684662, PMCID: PMC9851052, DOI: 10.1016/j.jacadv.2022.100157.Peer-Reviewed Original ResearchSevere maternal morbidityIschemic heart diseaseDelivery hospitalizationsComplex survey methodsCardiac diseaseCardiac diagnosisMaternal morbidityHeart diseasePre-existing ischaemic heart diseasePre-existing ischemic heart diseaseNontransfusion severe maternal morbidityWorld Health Organization classificationClass IAdverse pregnancy outcomesNationwide Readmissions DatabaseRelative risk regressionWorld Health Organization class IPregnancy outcomesPrimary outcomeRetrospective studyAdverse outcomesUnadjusted analysesOrganization classificationRisk regressionWorse outcomesUpdate of pediatric bone tumors—notochordal tumors, chondrogenic tumors, and vascular tumors of the bone
Lee H, Wang A, Cheng R, Moran J, Al-Dasuqi K, Irshaid L, Maloney E, Porrino J. Update of pediatric bone tumors—notochordal tumors, chondrogenic tumors, and vascular tumors of the bone. Skeletal Radiology 2022, 52: 1101-1117. PMID: 36369290, DOI: 10.1007/s00256-022-04235-x.Peer-Reviewed Original ResearchUpdate of pediatric bone tumors: osteogenic tumors and osteoclastic giant cell-rich tumors
Al-Dasuqi K, Cheng R, Moran J, Irshaid L, Maloney E, Porrino J. Update of pediatric bone tumors: osteogenic tumors and osteoclastic giant cell-rich tumors. Skeletal Radiology 2022, 52: 671-685. PMID: 36326880, DOI: 10.1007/s00256-022-04221-3.Peer-Reviewed Original ResearchData Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR)
Matias-Guiu X, Selinger CI, Anderson L, Buza N, Ellenson LH, Fadare O, Ganesan R, Ip PPC, Palacios J, Parra-Herran C, Raspollini MR, Soslow RA, Werner HMJ, Lax SF, McCluggage WG. Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal Of Gynecological Pathology 2022, 41: s90-s118. PMID: 36305536, DOI: 10.1097/pgp.0000000000000901.Peer-Reviewed Original ResearchConceptsEndometrial cancerCancer reportingWorld Health Organization classificationFemale genital tumorsCancer patient careCommon cancerOrganization classificationResection specimensClinical managementGenital tumorsPatient careCancerMolecular classificationCancer diagnosisExpert cliniciansExpert pathologistsNoncore elementsMajor advancesDetailed recommendationsReportingCancer dataInternational collaborationPrognosisNeoplasmsTumorsEffect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk J, Park S, Parekh N, Zheng K, Rudrapatna V, Syal G, Ha C, McGovern D, Melmed G, Fleshner P, Eisenstein S, Ramamoorthy S, Dulai P, Boland B, Grunvald E, Mahadevan U, Ohno-Machado L, Sandborn W, Singh S. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. The American Journal Of Gastroenterology 2022, 117: 1639-1647. PMID: 35973139, DOI: 10.14309/ajg.0000000000001855.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiologic-treated patientsRisk of hospitalizationBody mass indexNormal body mass indexSerious infectionsBiologic agentsBowel diseaseCox proportional hazards analysisWorld Health Organization classificationEffect of obesityProportional hazards analysisElectronic health recordsCause hospitalizationVisceral obesityAdult patientsBaseline demographicsBiologic initiationBiologic therapyCohort studyEndoscopic outcomesMass indexOrganization classificationTreatment characteristicsStratified analysisComparison of severe maternal morbidity in pregnancy by modified World Health Organization Classification of maternal cardiovascular risk
Denoble AE, Goldstein SA, Wein LE, Grotegut CA, Federspiel JJ. Comparison of severe maternal morbidity in pregnancy by modified World Health Organization Classification of maternal cardiovascular risk. American Heart Journal 2022, 250: 11-22. PMID: 35526569, PMCID: PMC9836743, DOI: 10.1016/j.ahj.2022.04.009.Peer-Reviewed Original ResearchConceptsSevere maternal morbidityWorld Health Organization classificationDelivery hospitalizationsCardiac diagnosisMaternal morbidityOrganization classificationMaternal cardiovascular riskNationwide Readmissions DatabaseRisk of deathSevere cardiac diseaseWeighted national estimateMWHO classificationDelivery admissionCardiovascular riskPregnant patientsSecondary outcomesPrimary outcomeRetrospective studyYear postpartumPregnancy counselingPrimary exposureMonths postpartumNationwide databaseCardiac diseaseElevated risk
2021
Gamma–Delta T‐cell Lymphomas
Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaHepatosplenic T-cell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaFive-year overall survivalCentral nervous system prophylaxisGamma delta T cellsWorld Health Organization classificationAggressive T-cell lymphomaExtensive skin ulcerationsCurative stem cell transplantationChronic antigenic stimulationStem cell transplantationInnate immune systemMost chemotherapeutic agentsSystemic methotrexateSystem prophylaxisMedian survivalMost patientsOverall prognosisOverall survivalClinical featuresOrganization classificationRisk factorsPreoperative Texture Analysis Using 11C-Methionine Positron Emission Tomography Predicts Survival after Surgery for Glioma
Manabe O, Yamaguchi S, Hirata K, Kobayashi K, Kobayashi H, Terasaka S, Toyonaga T, Magota K, Kuge Y, Tamaki N, Shiga T, Kudo K. Preoperative Texture Analysis Using 11C-Methionine Positron Emission Tomography Predicts Survival after Surgery for Glioma. Diagnostics 2021, 11: 189. PMID: 33525709, PMCID: PMC7911154, DOI: 10.3390/diagnostics11020189.Peer-Reviewed Original ResearchPositron emission tomographyOverall survivalEmission tomographyMET positron emission tomographyWorld Health Organization classificationMean standardized uptake valuePreoperative metabolic imagingPreoperative texture analysisMalignant brain tumorsStandardized uptake valueCause deathLow gray-level run emphasisContralateral cortexMET uptakeSingle centerPrognostic valueGrade IIIOrganization classificationTumor gradeUnivariate analysisGrade IIGrade IVBrain tumorsUptake valueSurvival curves
2020
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaAllogeneic hematopoietic cell transplantWorld Health Organization classificationAcute myeloid leukemia tumorsLeukemia tumorsOutcomes of patientsPost-remission therapyHematopoietic cell transplantMedian latency periodIndependent prognostic impactBone marrow evaluationAnti-leukemia therapyPET/CTCellular adhesion moleculesPatient characteristicsPrognostic impactLocal therapyCell transplantMarrow evaluationOrganization classificationConventional chemotherapyMyeloid leukemiaTherapeutic approachesReceptor/ligandGastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours
Quezada‐Marín J, Lam A, Ochiai A, Odze R, Washington K, Fukayama M, Rugge M, Klimstra D, Nagtegaal I, Tan P, Arends M, Goldblum J, Cree I, Salto‐Tellez M. Gastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology 2020, 77: 340-350. PMID: 32320495, DOI: 10.1111/his.14120.Peer-Reviewed Original ResearchConceptsWorld Health Organization classificationWorld Health Organization Classification of TumorsMolecular biomarkersClassification of tumorsEpithelial neoplasmsDigestive tumorsRoutine diagnosticsDevelopment of drugsOncological pathologyArtificial intelligence toolsTumorIntelligence toolsBiomarkersMethod of classification
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply